GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotest AG (OTCPK:BIESF) » Definitions » ROE % Adjusted to Book Value

Biotest AG (Biotest AG) ROE % Adjusted to Book Value : 10.93% (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Biotest AG ROE % Adjusted to Book Value?

Biotest AG's ROE % for the quarter that ended in Mar. 2024 was 22.95%. Biotest AG's PB Ratio for the quarter that ended in Mar. 2024 was 2.10. Biotest AG's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was 10.93%.


Biotest AG ROE % Adjusted to Book Value Historical Data

The historical data trend for Biotest AG's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotest AG ROE % Adjusted to Book Value Chart

Biotest AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.52 -4.37 -3.80 -1.96 11.73

Biotest AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.21 7.29 39.09 12.91 10.93

Competitive Comparison of Biotest AG's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Biotest AG's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotest AG's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotest AG's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Biotest AG's ROE % Adjusted to Book Value falls into.



Biotest AG ROE % Adjusted to Book Value Calculation

Biotest AG's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=29.56% / 2.52
=11.73%

Biotest AG's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=22.95% / 2.10
=10.93%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biotest AG ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Biotest AG's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotest AG (Biotest AG) Business Description

Industry
Traded in Other Exchanges
Address
Landsteinerstrasse 5, Dreieich, DEU, 63303
Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The operating business segments are Therapy, Plasma and Services, and Other segments. It generates maximum revenue from the Therapy segment. Geographically, it derives a majority of revenue from Central Europe and also has a presence in other countries.

Biotest AG (Biotest AG) Headlines

From GuruFocus

Nine Months 2020 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q4 2020 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Full Year 2019 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q4 2021 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q3 2021 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q3 2022 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q4 2022 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Nine Months 2019 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024